Company: ARWR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001628280-25-004634
Chunk: 12

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part I, Item 1
Chunk 12
---
ITEM 1.    FINANCIAL STATEMENTS 

Arrowhead Pharmaceuticals, Inc.

Consolidated Balance Sheets 

(in thousands, except per share amounts)

December 31, 2024September 30, 2024(unaudited)ASSETSCurrent assets:Cash, cash equivalents and restricted cash$53,889 $102,685 Accounts receivable2,500 — Available-for-sale securities, at fair value499,046 578,276 Prepaid expenses9,366 9,537 Other current assets5,735 4,973 Total current assets570,536 695,471 Property, plant and equipment, net387,069 386,032 Intangible assets, net8,137 8,562 Right-of-use assets44,869 45,255 Other assets3,083 4,482 Total Assets$1,013,694 $1,139,802 LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable$14,457 $11,388 Accrued expenses59,401 63,017 Accrued payroll and benefits11,275 21,989 Lease liabilities6,560 6,342 Credit facility1,625 — Other liabilities440 432 Total current liabilities93,758 103,168 Long-term liabilities:Lease liabilities, net of current portion109,296 111,027 Liability related to the sale of future royalties346,776 341,361 Credit facility, net of current portion407,789 393,183 Total long-term liabilities863,861 845,571 Commitments and contingencies (Note 7)Noncontrolling interest and stockholders’ equity:Common stock, $0.001 par value:Authorized 290,000 shares; issued and outstanding 125,572 and 124,376 shares218 217 Additional paid-in capital1,846,842 1,806,000 Accumulated other comprehensive income4,137 4,750 Accumulated deficit(1,798,608)(1,625,523)Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity52,589 185,444 Noncontrolling interest3,486 5,619 Total noncontrolling interest and stockholders’ equity56,075 191,063 Total Liabilities, Non